Lowering biotech venture risk through marginal cost structures
The speaker outlined an investment thesis focused on lowering the fixed costs of biotech venture investing by operating shared internal labs and leveraging genetics-based target validation.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.